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A B S T R A C T
Background: The outcome of percutaneous coronary intervention (PCI) has been reported to be poor in
hemodialysis (HD) patients even in the drug-eluting stent era. We have reported relatively poor
outcomes after sirolimus-eluting stent implantation in the OUCH study.
Methods: The OUCH-TL study is a prospective, non-randomized, single-arm registry designed to assess the
results of paclitaxel-eluting stent (PES) in HD patients with follow-up quantitative coronary angiography
analysis. The primary endpoint was the occurrence of target-vessel failure (TVF) deﬁned as cardiac death,
myocardial infarction (MI), and target-vessel revascularization (TVR) at 12 months.
Results: A total of 119 patients with 154 lesions were enrolled (one withdrawal). Mean age was 65  10 years,
male gender was 79%, 89% of cases had stable coronary disease. Diabetic nephropathy was diagnosed in 61% of the
patients. American College of Cardiology/American Heart Association type B2/C accounted for 96% of lesions and
22.7% of lesions were treated with Rotablator (Boston Scientiﬁc Corporation, Natick, MA, USA). Rates of TVF, death,
MI, stent thrombosis and TVR at 12 months were 20.2%, 5.9%, 5.0%, 1.4%, and 12.6%, respectively. TVR was performed
in 8.4% of the patients up to 12 months. Late loss in-stent was 0.48  0.61 mm, and late loss in-segment was
0.37  0.61 mm at 9 months. Binary restenosis in-stent was 10.3% and in-segment was 14.5%.
§
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Renal insufﬁciency has been associated with poor prognosis
in coronary artery disease patients [1–7]. Among patients with
chronic kidney disease, those undergoing hemodialysis (HD)
includes especially one of the highest risk subsets of patients with
10–20 times higher cardiovascular mortality rate than the general
population [8]. Drug-eluting stents (DESs) have been expected to be
the Messiah to improve patients’ prognosis with hemodialysis.
However, the results of clinical studies using DES in dialysis patients
remain to be improved in several reports [9,10]. HD was a predictor
of adverse events among all patients with sirolimus-eluting stent
(SES) implantation [9,11–14]. We have also previously reported a
relatively poor outcome and bimodal restenotic response of SES in a
multicenter prospective registry [15]. Paclitaxel-eluting stents (PES)
have been utilized as one of the workhorse DES for several years
reducing target lesion revascularization (TLR) as compared to bare
metal stents (BMS) [16]. It has been reported that PES was superior
to SES in the outcome of HD patients in a few single center analyses
[17–19]. Therefore, we conducted this prospective non-randomized
multicenter trial of PES implantation in a group of HD patients
using quantitative coronary angiography (QCA) carried out in an
independent core laboratory.
Methods
Study design and patient population
The OUCH-TL study (outcome in hemodialysis of TAXUS
Liberte) is a prospective multicenter registry study targeting the
outcome of PES implantation in patients undergoing maintenance
hemodialysis following the same protocol as in the OUCH registry
[15]. Inclusion criteria were end-stage renal disease requiring HD,
age 21 years, and elective percutaneous coronary intervention
(PCI) with PES. Exclusion criteria were a history of surviving an
episode of sudden death, cardiogenic shock, emergency PCI, ST-
segment elevation myocardial infarction (MI), intolerance to
antiplatelet drugs, coronary stenting within 6 months, in-stent
restenosis following DES implantation, MI within 30 days, severe
valvular heart disease, critical limb ischemia, and total occlusion of
the target vessel. All patients received information about the
inclusion and exclusion criteria for the study, and gave written
informed consent. Consecutive patients subjected to the inclusion
and exclusion criteria were recruited in the study.
PCI procedures were performed at the discretion of the operator
and with the objective of achieving optimal results, although in
elective situations the use of PES (TAXUS Liberte, Boston Scientiﬁc
Corporation, Natick, MA, USA) was mandatory. Use of other DES
was prohibited. Rotational atherectomy (RotablatorTM, Boston
Scientiﬁc) was available in the majority of the participating centers
except for 2 centers, and was allowed to be used whenever
necessary. Use of intravascular ultrasound (IVUS) to conﬁrm
optimal stent expansion was encouraged.
Follow-up was started from the date of the PCI. Planned staged
PCI procedures were not considered as adverse events. The ‘‘target
lesion’’ was deﬁned at the time of the initial PCI. Follow-up clinical
data were collected at 1, 8, and 12 months, and follow-up coronary
angiography was performed in 74% of patients at 8 months. Allpatients received antiplatelet agents, both aspirin 80–200 mg/day
and a thienopyridine derivative (clopidogrel 75 mg or ticlopidine
200 mg/day). Maintenance hemodialysis was performed 3 times a
week using a high performance membrane.
Data management and deﬁnitions
Data were collected and submitted from the participating sites
using case record forms and study codes to protect subject identity.
An independent contract research organization, Cardiocore Japan
(Tokyo, Japan), was retained to serve as the administrator of the
study.
In the presence of Thrombosis in Myocardial Infarction (TIMI)
grade 3 ﬂow, angiographic success was deﬁned as the achieve-
ment of a minimum stenosis diameter reduction to <50%. Overall
procedural success was deﬁned as presence of angiographic
success plus absence of a major complication, and procedural
failure as either lack of angiographic success or occurrence of a
major complication.
All the angiographic data were transmitted to the independent
core laboratory (Cardiocore Japan) and assessed by experts blinded
to patient data. QCA was carried out in the core laboratory using
CAAS 5.9 (Pie Medical Imaging, Maastricht, The Netherlands).
The primary endpoint of the study was occurrence of target-
vessel failure (TVF), deﬁned as cardiac death, MI in the target
vessel, and the requirement for target-vessel revascularization
(TVR) within the ﬁrst year after PCI. Major adverse coronary events
(MACE) were deﬁned as death, MI, repeat PCI, or coronary artery
bypass graft surgery (CABG). Deaths were classiﬁed as cardiac or
non-cardiac. Sudden death due to an unknown cause was classiﬁed
as a cardiac death. Repeat PCI was categorized as target lesion,
target vessel or non-target vessel revascularization according to
whether the index lesion or artery was involved. Stent thrombosis
was categorized as deﬁnite, probable, or possible according to the
Academic Research Consortium (ARC) deﬁnition [20]. Sample size
followed the previous study as already published [15].
Statistical analysis
Continuous variables were expressed as mean  SD and were
compared with the Student unpaired t test. Categorical variables were
expressed as counts and percentages, and the chi-square test was
used for comparison. Cumulative one-year adverse event rates were
estimated according to the Kaplan–Meier method and compared by
the log-rank test. Stepwise logistic analysis was performed to detect
predictors of groups. All analyses were performed with the SPSS 19
(IBM, New York, NY, USA).
Results
Baseline and procedural characteristics
A total of 120 patients who fulﬁlled the inclusion criteria were
enrolled in the study. Patient ﬂow is shown in Fig. 1. After an initial
successful PCI, consent was withdrawn by 1 patient, and
119 individuals completed the study. A total of 154 target lesions
were treated with study stents in these 119 patients. Clinical
follow-up was available in 97.5% of patients at 12 months and
120
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Death
1
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Death 6
Lost to follow-up 3
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Fig. 1. Patient ﬂow.
Table 2
Lesion characteristics and coronary intervention procedures.
Number of lesions 154
Target vessels
LMCA (%) 3 (1.9)
LAD (%) 57 (37.0)
LCX (%) 30 (19.5)
RCA (%) 64 (41.6)
ACC/AHA classiﬁcation
A (%) 2 (1.3)
B1 (%) 4 (2.6)
B2 (%) 73 (47.4)
C (%) 75 (48.7)
TIMI ﬂow
TIMI 0 (%) 4 (2.6)
TIMI 1 (%) 1 (0.6)
TIMI 2 (%) 3 (1.9)
TIMI 3 (%) 146 (94.8)
Lesion length
Discrete (10 mm, %) 24 (15.6)
Tubular (10–20 mm, %) 65 (42.2)
Diffuse (>20 mm, %) 65 (42.2)
Moderate/severe calciﬁcation (%) 116 (75.4)
Severe tortuosity 11 (7.1)
Eccentric lesion (%) 90 (58.4)
Thrombus (%) 0 (0)
Ulceration (%) 6 (3.9)
Aneurysm (%) 4 (2.6)
Irregular lesion surface (%) 79 (51.3)
Lesion bending >45 degree (%) 32 (20.8)
Ostial lesion (%) 28 (18.2)
De novo lesion (%) 154 (100)
Bifurcation 63 (40.9)
Side branch protection with guidewire 43 (27.9)
Rotational atherectomy (%) 35 (22.7)
Stent size
3.5 mm (%) 46 (32.6)
3.0 mm (%) 50 (35.5)
2.75 mm (%) 14 (9.9)
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88 patients (74%) at 8 months.
Overall, the mean age of patients was 65 years; 79% were male,
87% had hypertension; and 55% had diabetes (Table 1). The average
duration of hemodialysis was 73  76 months. Multivessel disease
was present in 34%; and non-protected left main disease in 3%. The
mean ejection fraction was 56  14%. Baseline blood tests showed a
mean B-type natriuretic peptide (BNP) level of 613.8  816.0 pg/mL
(normal <18.4 pg/mL). Peripheral artery disease and cerebrovascular
disease were found in 22.7% and 16.8%, respectively.
Lesion characteristics are shown in Table 2. American Heart
Association/American College of Cardiology type B2 and C lesions
were present in 47.4% and 48.7%, respectively. Angiographic
moderate/severe calciﬁcation was found in 75.4%. Rotational
atherectomy was employed in 22.7% of lesions, and bifurcation
lesions were present in 41%.Table 1
Patient characteristics.
Patient number 119
Male gender (%) 94 (79.0)
Age (years) 64.8  9.6
Height (cm) 161.7  8.7
Weight (kg) 59.8  12.5
Hypertension (%) 104 (87.4)
Dyslipidemia (%) 54 (45.0)
Current smoking (%) 53 (44.2)
Peripheral artery disease (%) 27 (22.7)
Cerebrovascular disease (%) 20 (16.8)
Family history of CAD (%) 7 (5.9)
Diabetes mellitus (%) 65 (55.0)
Insulin use 32 (26.9)
Reason of renal failure
Diabetic nephropathy (%) 73 (60.8)
Non-diabetic nephropathy (%) 46 (39.2)
Duration of hemodialysis (months) 73.3  75.6
Diagnosis
Stable angina (%) 71 (59.7)
Unstable angina (%) 13 (10.9)
Asymptomatic ischemia (%) 35 (29.4)
Prior myocardial infarction (%) 21 (17.3)
Prior PCI (%) 34 (28.6)
Prior CABG (%) 10 (8.4)
Number of diseased vessels
1 (%) 76 (63.9)
2 (%) 27 (23.5)
3 (%) 12 (10.1)
Non-protected left main disease (%) 3 (2.5)
Ejection fraction (%) 55.8  14.4
BNP (pg/mL) 613.8  816.0
CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG,
coronary artery bypass graft; BNP, B-type natriuretic peptide.
2.5 mm (%) 31 (22.0)
Mean stent length (mm) 19.6
ACC, American College of Cardiology; AHA, American Heart Association; LMCA,
left main coronary artery; LAD, left anterior descending coronary artery; LCX,
left circumﬂex coronary artery; RCA, right coronary artery; TIMI, thrombolysis
in myocardial infarction.Quantitative coronary angiography data
QCA was performed in an independent core laboratory, and data
are shown in Table 3. Average in-stent late loss was 0.48  0.61 mm
and in-segment late loss was 0.37  0.61 mm. Binary restenosis in-
stent was 10.3% and that in-segment was 14.5%. Patterns of restenosis
were 53% of focal, 29% of diffuse, and 18% of occlusion. Histogram of late
loss is demonstrated in Fig. 2A and B, which had normal distribution
both in diabetic and non-diabetic patients. Mean in-stent late loss in
diabetic patients was 0.39  0.53 mm, whereas that in other patients
was 0.58  0.70 mm (p = 0.112).
Clinical follow-up data
The mortality rate at one year was 5.9%, with 4.2% cardiac and
1.7% non-cardiac deaths (Table 4). Myocardial infarction was
observed in 5% of patients, and repeat revascularization for the
target lesions was carried out in 8.4% (all patients were treated
with PCI, half of them were symptomatic), 4.2% with non-target
lesion TVR, and 3.4% with non-TVR. Deﬁnite/probable stent
thrombosis occurred in 1.7% of patients according to the ARC
deﬁnition (0.8% early and 0.8% late). TVF, the primary endpoint,
was present in 16.7% of patients. TVF-free survival rate for this
registry is shown in Fig. 3A. When comparing patients with
diabetic nephropathy to non-diabetic patients, no difference was
observed between the 2 groups (Fig. 3B). Univariate analysis of the
Table 3
Results of sub-segmental quantitative coronary angiographic analysis (N = 154).
Proximal edge (N = 120) In-stent (N = 154) Distal edge (N = 154) In-segment (N = 154)
Reference diameter
Pre-procedure (mm) NA NA NA 2.83  0.65
Post-procedure (mm) 3.20  0.59 2.90  0.60 2.76  0.61 2.80  0 63
8 months follow-up (mm) 3.08  0.58 2.82  0.55 2.68  0.56 2.76  0.57
Minimal lumen diameter
Pre-procedure (mm) NA NA NA 0.86  0.42
Post-procedure (mm) 2.77  0.69 2.53  0.51 2.33  0.68 2.22  0.59
8 months follow-up (mm) 2.56  0.82 2.10  0.74 2.21  0.74 1.90  0.72
% diameter stenosis
Pre-procedure (%) NA NA NA 69.7  12.8
Post-procedure (%) 13.8  8.9 12.2  8.1 16.5  11.5 20.9  9.6
8 months follow-up (%) 17.1  18.6 25.9  20.5 18.2  19.1 31.7  20.2
Late loss (mm) 0.28  0.58 0.48  0.61 0.17  0.52 0.37  0.61
Restenosis 4 (4.4%) 12 (10.3%) 7 (6.0%) 17 (14.5%)
Fig. 2. Histogram of in-stent late loss. (A) Diabetic nephropathy patients. (B) Other patients (non-diabetic nephropathy patients).
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Fig. 4. Presence of peripheral artery disease and use of Rotablator
showed higher TVF rates than absence of those factors. Indepen-
dent predictors for TVF were identiﬁed by multivariate stepwiseTable 4
Clinical follow-up data at 1 year.
Total 30 days 12 months
Number of patients 119 119 110
Death (%) 7 (5.9) 1 (0.8%) 6 (5.5%)
Cardiac death (%) 5 (4.2) 1 (0.8%) 4 (3.6%)
Non cardiac death (%) 2 (1.7) 0 (0.0%) 2 (1.8%)
Myocardial infarction (%) 6 (5.0) 4 (3.4%) 2 (1.8%)
Stroke (%) 4 (3.4) 0 (0.0%) 4 (3.6%)
TLR (%) 10 (8.4) 0 (0.0%) 10 (9.1%)
Non-TL TVR (%) 5 (4.2) 0 (0.0%) 5 (4.5%)
Non-TVR (%) 4 (3.4) 1 (0.8%) 3 (2.7%)
Stent thrombosis (%) 2 (1.7) 1 (0.8%) 1 (0.8%)
Admission due to heart failure (%) 4 (3.4) 0 (0.0%) 4 (3.4%)
TVF (%) 24 (20.2) 4 (3.4%) 20 (18.2%)
TL, target lesion; TLR, target lesion revascularization; TVR, target vessel
revascularization; TVF, target vessel failure.logistic regression analysis. Multivessel disease (odds ratio 3.71,
95% CI 1.07–12.87, p = 0.04), use of Rotablator (odds ratio 3.54, 95%
CI 1.20–10.39, p = 0.02), and presence of peripheral artery disease
(odds ratio 3.14, 95% CI 1.07–9.17, p = 0.04) were the independent
predictors for TVF in the current study.
Discussion
In the current study, TVF at one year after PES implantation
was 16.7%, and average in-stent late loss at 8 months was
0.48  0.61 mm in patients undergoing maintenance HD. Although
this was not a randomized trial, the results appear favorable when
comparing with the prior report following SES implantation with
similar inclusion and exclusion criteria (TVF of 24.9% and mean in-
stent late loss of 0.69 mm) [15]. The results of the current trial were
also comparable to those of the Japanese real world registry of
patients undergoing PES implantation [21]. Patients with diabetic
nephropathy demonstrated similar outcomes to non-diabetic
patients.
Outcomes of HD patients have been reported to be one of the
worst subsets in coronary heart disease. Several issues have been
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restenosis rates after PCI have been reported to be extremely high
even using DES [10,15,22]. Furthermore, severe calciﬁed lesions
requiring rotational atherectomy was one of the predictors for TVF.
This ﬁnding is consistent with previous reports [23]. Second,
cardiovascular events other than revascularization occur frequent-
ly. In fact, peripheral artery disease and extensive coronary disease
are the signiﬁcant predictors of subsequent events in this study.
Third, in HD patients, there are some unstable conditions
associated with the process of HD. Hemodynamic condition such
as extracellular volume and blood pressure changes drastically
during HD and thrombogenicity may be induced by the HD circuit.
Finally, diabetic nephropathy is the major cause for HD and for the
increase of cardiovascular events. In the current study, 66% of the
cases had diabetic nephropathy. Interestingly, there were no
differences in TVF between diabetic and non-diabetic groups by
means of PES implantation.
It has been reported that PES demonstrated better outcomes in
terms of angiographic restenosis and TLR than SES in the treatment
of HD patients in several single-center studies [17–19]. In our
previous report, histogram of in-stent late loss demonstrated
bimodal distributions, which showed a high in-stent late loss of
0.69  0.93 mm after SES implantation [15]. It has been demonstrat-
ed that SES was not effective in inhibiting restenosis especially in the
severe calciﬁed lesions in that report [15]. Distribution of late loss
was normal and an average in-stent late loss at 8 months was
0.48  0.61 mm after PES implantation, although Rotablator usage
was also associated with TVF in the current study. Yano et al. have
demonstrated lower inﬂammatory response after PES implantation as
compared to SES in patients on HD [24]. Paclitaxel is a hydrophobic
potent anti-neoplastic agent and inhibits leptin. Severe calciﬁed
lesions may interfere with the diffusion of the more hydrophilic anti-
proliferative drugs such as sirolimus. Therefore, PES may be less
inﬂuenced by the adverse lesion conditions than SES. PES also
demonstrated equivalent efﬁcacy in diabetic patients as compared to
non-diabetic patients, whereas outcomes are different betweenaryarterybypass  graft;3VD,triplevesseldisease includingleftmaindisease;EF/5%,ejection
; CVD, cerebrovascular disease; DM, diabetes mellitus; IVUS, intravascular ultrasound.
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PES has little market share at present. Paclitaxel-coated balloon with
BMS implantation may be a future option to obtain better outcomes
than the limus-DESs in HD patients.
There are several limitations to this study. This was a
prospective but non-randomized study. The number of cases
may be insufﬁcient. However, most studies reporting the outcomes
of DES implantation in treating HD patients have included fewer
than 100 cases. Second, although consecutive patients should be
enrolled in the study by protocol, the number of patients who met
inclusion and exclusion criteria was not registered during the
same period. Third, since 60% of cases were diabetic and severely
diseased patients, evaluation for ischemia was not performed
before TVR which might have increased event rates. However,
restenotic response of PES was properly assessed by the QCA in the
current study.
In conclusion, the TVF rate following PES implantation in HD
patients appears favorable as compared to that of SES in the
previous study. Outcomes of PES implantation in HD patients
appears comparable to those of non-HD patients.
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